AI Science Tracker

Institute of Molecular Biology Mainz

1 discovery from 2024

Discoveries

AlphaFold-Multimer-guided experiments corroborate six novel human protein interfaces

Researchers developed a fragmentation strategy for AlphaFold-Multimer and applied it to 62 human protein interactions associated with neurological disorders. Eighteen predicted structures were judged correct or likely correct, and experiments corroborated six previously unreported interfaces: FBXO23–STX1B, STX1B–VAMP2, ESRRG–PSMC5, PEX3–PEX19, PEX3–PEX16 and SNRPB–GIGYF1.

Technology: AlphaFold-Multimer with a protein-fragmentation strategy

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Eighteen predicted structures were judged correct or likely correct, and experiments corroborated six previously unreported interfaces: FBXO23–STX1B, STX1B–VAMP2, ESRRG–PSMC5, PEX3–PEX19, PEX3–PEX16 and SNRPB–GIGYF1.
  • Still unknown: The article reports 18 correct or likely correct models among 62 interactions and experimental support for six interfaces; these are not a comprehensive interactome map. AlphaFold-Multimer showed limited specificity and was sensitive to input-fragment length, as the source explicitly notes.
  • AI role: AlphaFold-Multimer predicted domain–motif interface structures; researchers tested predictions and used the model-informed fragmentation strategy to prioritize interaction interfaces. Wet-lab assays corroborated six novel contacts, while the tool had limited specificity and performance declined with longer/full-length input sequences.

Evidence sources: https://link.springer.com/article/10.1038/s44320-023-00005-6

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 119 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.